ERBB2 and breast carcinoma: Arthralgia, diarrhea, and fatigue were indeed the most commonly reported AEs in HER2-positive breast cancer patients under treatment with s.c trastuzumab in combination with chemotherapy (Ismael et al., 2012; Gligorov et al., 2017).